Teva Pharms Inc Company Profile
What is the competitive landscape for TEVA PHARMS INC
TEVA PHARMS INC has sixteen approved drugs.
There is one US patent protecting TEVA PHARMS INC drugs. There are three tentative approvals on TEVA PHARMS INC drugs.
Summary for Teva Pharms Inc
| US Patents: | 1 |
| Tradenames: | 16 |
| Ingredients: | 16 |
| NDAs: | 16 |
Drugs and US Patents for Teva Pharms Inc
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Teva Pharms Inc | ATORVASTATIN CALCIUM | atorvastatin calcium | TABLET;ORAL | 220276-004 | Nov 13, 2025 | AB | RX | No | No | ⤷ Start Trial | ⤷ Start Trial | ||||
| Teva Pharms Inc | NILOTINIB HYDROCHLORIDE | nilotinib hydrochloride | CAPSULE;ORAL | 219134-001 | Jun 26, 2026 | AB | RX | No | No | ⤷ Start Trial | ⤷ Start Trial | ||||
| Teva Pharms Inc | AMLODIPINE BESYLATE | amlodipine besylate | TABLET;ORAL | 219686-002 | Jan 22, 2026 | DISCN | No | No | ⤷ Start Trial | ⤷ Start Trial | |||||
| Teva Pharms Inc | ATORVASTATIN CALCIUM | atorvastatin calcium | TABLET;ORAL | 220276-001 | Nov 13, 2025 | AB | RX | No | No | ⤷ Start Trial | ⤷ Start Trial | ||||
| Teva Pharms Inc | MESALAMINE | mesalamine | TABLET, DELAYED RELEASE;ORAL | 213191-001 | Aug 22, 2024 | AB | RX | No | No | ⤷ Start Trial | ⤷ Start Trial | ||||
| Teva Pharms Inc | TIOPRONIN | tiopronin | TABLET, DELAYED RELEASE;ORAL | 216456-001 | Jul 22, 2024 | AB | RX | No | No | ⤷ Start Trial | ⤷ Start Trial | ||||
| Teva Pharms Inc | CETRORELIX ACETATE | cetrorelix acetate | POWDER;SUBCUTANEOUS | 215737-001 | Aug 12, 2022 | DISCN | No | No | ⤷ Start Trial | ⤷ Start Trial | |||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for Teva Pharms Inc Drugs
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| European Patent Office | 3692021 | ⤷ Start Trial |
| World Intellectual Property Organization (WIPO) | 2019071111 | ⤷ Start Trial |
| >Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for Teva Pharms Inc Drugs
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 2059246 | 122024000070 | Germany | ⤷ Start Trial | PRODUCT NAME: KOMBINATION AUS (A) MACITENTAN ODER EINEM PHARMAZEUTISCH AKZEPTABLEN SALZ DAVON UND (B) TADALAFIL ODER EINEM PHARMAZEUTISCH AKZEPTABLEN SALZ DAVON; AUTHORISATION NO/DATE: EU/1/24/1859 20240927 |
| 1343782 | 28/2010 | Austria | ⤷ Start Trial | PRODUCT NAME: PAZOPANIB, GEGEBENENFALLS IN FORM EINES PHARMAZEUTISCH ANNEHMBAREN SALZES ODER SOLVATS DAVON; REGISTRATION NO/DATE: EU/1/10/628/001 - EU/1/10/628/004 20100614 |
| 1534390 | 91 3-2010 | Slovakia | ⤷ Start Trial | PRODUCT NAME: ELTROMBOPAG; REGISTRATION NO/DATE: EU/1/10/612/001 - EU/1/10/612/006 20100315 |
| 2059246 | LUC00371 | Luxembourg | ⤷ Start Trial | PRODUCT NAME: A COMBINATION OF (A) MACITENTAN OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF AND (B) TADALAFIL OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF; AUTHORISATION NUMBER AND DATE: EU/1/24/1859 20240930 |
| 2059246 | 301308 | Netherlands | ⤷ Start Trial | PRODUCT NAME: EEN COMBINATIE VAN (A) MACITENTAN OF EEN FARMACEUTISCH AANVAARDBAAR ZOUT DAARVAN EN (B) TADALAFIL OF EEN FARMACEUTISCH AANVAARDBAAR ZOUT DAARVAN; REGISTRATION NO/DATE: EU/1/24/1859 20240930 |
| 2059246 | PA2024537 | Lithuania | ⤷ Start Trial | PRODUCT NAME: (A) MACITENTANO ARBA JO FARMACINIU POZIURIU PRIIMTINOS DRUSKOS IR (B)TADALAFILIO ARBA JO FARMACINIU POZIURIU PRIIMTINOS DRUSKOS DERINYS; REGISTRATION NO/DATE: EU/1/24/1859 20240927 |
| 2101777 | 201640021 | Slovenia | ⤷ Start Trial | PRODUCT NAME: AMBRISENTAN IN COMBINATION WITH TADALAFIL; NATIONAL AUTHORISATION NUMBER: EU/1/08/451/001-004; DATE OF NATIONAL AUTHORISATION: 20151120; AUTHORITY FOR NATIONAL AUTHORISATION: EU |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
